Publicaciones en colaboración con investigadores/as de University Medical Center Utrecht (27)

2023

  1. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study

    Vaccine, Vol. 41, Núm. 1, pp. 251-262

  2. Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

    Drug Safety, Vol. 46, Núm. 7, pp. 689-702

  3. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis

    Frontiers in Pharmacology, Vol. 14

2022

  1. Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries

    Frontiers in Pharmacology, Vol. 13

2021

  1. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)

    Frontiers in Pharmacology, Vol. 12

  2. Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project

    Drug Safety, Vol. 44, Núm. 3, pp. 383-395

  3. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies

    Pharmacoepidemiology and Drug Safety, Vol. 30, Núm. 10, pp. 1339-1352

  4. Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban—A European comparative drug utilization study

    Basic and Clinical Pharmacology and Toxicology, Vol. 128, Núm. 3, pp. 440-454

2020

  1. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations

    Vaccine, Vol. 38, pp. B8-B21

  2. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling

    Vaccine, Vol. 38, pp. B65-B75

  3. ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example

    Vaccine, Vol. 38, pp. B22-B30

  4. ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination

    Vaccine, Vol. 38, pp. B38-B46

  5. ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data

    Vaccine, Vol. 38, pp. B47-B55

  6. Advance system testing: Vaccine benefit studies using multi-country electronic health data – The example of pertussis vaccination

    Vaccine, Vol. 38, pp. B31-B37

  7. Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries – The ADVANCE project

    Vaccine, Vol. 38, Núm. 16, pp. 3243-3254

  8. Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project

    Vaccine, Vol. 38, pp. B56-B64

2019

  1. Estimation of vaccination coverage from electronic healthcare records; methods performance evaluation – A contribution of the ADVANCE-project

    PLoS ONE, Vol. 14, Núm. 9

  2. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross-national drug utilization study

    British Journal of Clinical Pharmacology, Vol. 85, Núm. 11, pp. 2524-2539

2016

  1. Case-only designs for studying the association of antidepressants and hip or femur fracture

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 103-113

  2. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: A cross-national descriptive study from the PROTECT-EU Project

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 56-65